| Zdroj: |
Gredal, O, Werdelin, L, Bak, S, Christensen, P B, Boysen, G, Kristensen, M O, Jespersen, J H, Regeur, L, Hinge, H H & Jensen, T S 1997, ' A clinical trial of dextromethorphan in amyotrophic lateral sclerosis ', Acta Neurologica Scandinavica, vol. 96, no. 1, pp. 8-13 . |
| Popis: |
INTRODUCTION: Although the cause of amyotrophic lateral sclerosis (ALS) is unknown, excitotoxicity mediated by glutamate has been implicated. Dextromethorphan is a NMDA-glutamate receptor antagonist with neuroprotective properties.MATERIAL AND METHODS: The effect of treatment with dextromethorphan (150 mg daily) in ALS patients was evaluated in a randomized, double-blind, placebo-controlled study. Forty-five patients were included in the analysis.RESULTS: At the end of the treatment period, 12 months after randomization, 15 patients (65%) in the placebo group and 12 patients (55 %) in the dextromethorphan group were still alive (log rank test, P=0.49). Rates of disease progression, as expressed by rates of decline in pulmonary function and in functional disability, were similar in both groups except for a significantly less pronounced rate of decline in the ability scores for the lower extremities in the dextromethorphan group.CONCLUSION: Treatment with a relatively low dose of dextromethorphan did not result in an improvement in 12-month survival in ALS. |
